Some U.S. Employers Plan to End Coverage of Weight-Loss Drugs as Costs Continue to Rise
Large employers in the United States are increasingly reconsidering coverage for GLP-1 weight-loss medications such as Wegovy, Zepbound, and Foundayo as growing demand continues to drive healthcare costs higher. According to recent surveys, around...
Novo Nordisk Cuts Wegovy Prices with New Subscription Plan to Boost U.S. Access
Novo Nordisk has introduced a discounted subscription plan for its blockbuster obesity drug Wegovy in the United States, aiming to expand access for patients paying out of pocket and regain momentum against rival Eli...